ARTICLE | Clinical News
KS Biomedix announces Phase II results
February 28, 2000 8:00 AM UTC
KS Biomedix (LSE:KSB) said its 131-patient, Phase II trial of CBF-BS2 to treat rheumatoid arthritis showed the compound to significantly reduce symptoms versus placebo after 28 days. Full analysis of ...